POM3
PreclinicalSmall molecule
POM3 is one of 17 small molecule programs targeting Hypertriglyceridemia. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Hypertriglyceridemia
#DrugCompanyPhaseTrials
1Lopid
PfizerApproved
Crestor
AstraZenecaApproved
Selzentry
GSKApproved
Cipro
BayerApproved
Topamax
WWim Janssens
Approved
Zocor
OOrganon and Co
Approved
Tryngolza (autoinjector)
Ionis PharmaceuticalsPhase 3
Redemplo
Arrowhead PharmaceuticalsPhase 3
SHR-1918
BBeijing Suncadia Pharmaceuticals Co., Ltd
Phase 3
Avandia
Jazz PharmaceuticalsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for POM3. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PProvident Clinical Research